EPA omega-3 fatty acid and CoQ10 may significantly reduce prostate-specific antigen (PSA) levels in normal healthy men.
Omega-3 fatty acid eicosapentaenoic acid (EPA) and coenzyme Q10 (CoQ10) may significantly reduce prostate-specific antigen (PSA) levels in normal healthy men, according to an Iranian study published in the British Journal of Nutrition. (Study published online November 30, 2012, ahead of print.) PSA levels are considered a marker for prostate cancer risk.
The randomized, double-blind study on 504 healthy men set out to determine whether omega-3 fatty acids, omega-6 fatty acids, or CoQ10 could alter serum PSA levels. For 12 weeks, subjects were randomly assigned to a dietary supplement of two capsules, twice daily, of placebo, omega-3 (1.2 g of EPA omega-3 and 0.72 g of docosahexaenoic acid, or DHA, omega-3 per capsule), omega-6 fatty acids (600 mg of gamma-linolenic acid, or GLA, per capsule), and CoQ10 (100 mg per capsule). Serum levels of PSA, EPA, DHA, GLA, lipid profile, and reproductive hormones were measured.
According to researchers, EPA significantly reduced serum PSA levels by 30% from baseline, and CoQ10 supplementation reduced serum PSA levels by 33%. However, supplementation with GLA significantly increased PSA levels by 15%.
The omega-3 supplement used in the study was Epax 5500 TG, an omega-3 triglyceride concentrate from omega-3 supplier Epax AS (Oslo, Norway). The CoQ10 was the Nutri Q10 brand.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.